Nasdaq Bio Leaves Singapore for the U.S.: Headquarters Relocation Hearing Approaches

Wave Life Sciences Ltd. announced that the Singapore High Court will hear its application to convene a shareholders’ meeting for a scheme of arrangement under Section 210 of the Singapore Companies Act on April 29, 2026. The application seeks shareholder approval to redomicile the group’s holding company from Singapore to the United States. The court has also set deadlines for filing affidavits and written submissions, with final redomiciliation subject to both shareholder and court approval.

On April 15, the board unanimously approved the redomiciliation plan, which involves establishing a new Delaware holding company, Wave Life Sciences, Inc., and exchanging existing Singapore ordinary shares for new shares on a one-for-one basis. Upon completion, the company’s ticker symbol, WVE, will remain unchanged on the Nasdaq Global Market. The company anticipates that this move will strengthen its corporate governance and regulatory alignment in the U.S. market while achieving greater cost efficiencies in compliance.

Wave Life Sciences is a clinical-stage RNA therapeutics company developing candidates such as WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency, and WVE-008 for liver diseases. Its platform leverages RNA interference, RNA editing, and splicing modulation technologies. The company is targeting U.S. and European markets with well-defined genetic diseases and, according to its latest disclosures, has secured sufficient cash to fund operations through the third quarter of 2028 to advance its key pipeline programs and regulatory strategy.